USD 8.36
(2.96%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | -864.4 Million USD | 69.57% |
2022 | -2.2 Billion USD | -20.81% |
2021 | -1.82 Billion USD | -1234.38% |
2020 | -137.02 Million USD | -91.38% |
2019 | -71.59 Million USD | 0.0% |
2001 | -234.5 Million USD | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q1 | -158.73 Million USD | -2.77% |
2024 Q2 | -150.53 Million USD | -40.45% |
2023 Q3 | -286.39 Million USD | -55.52% |
2023 Q1 | -215.74 Million USD | 8.0% |
2023 FY | -672.23 Million USD | 69.57% |
2023 Q2 | -184.15 Million USD | 14.64% |
2023 Q4 | -154.45 Million USD | 46.07% |
2022 Q3 | -653.02 Million USD | -0.94% |
2022 FY | -2.2 Billion USD | -20.81% |
2022 Q2 | -646.9 Million USD | 4.09% |
2022 Q1 | -674.51 Million USD | 59.96% |
2022 Q4 | -234.5 Million USD | 64.09% |
2021 FY | -1.82 Billion USD | -1234.38% |
2021 Q4 | -1.68 Billion USD | -6216.49% |
2021 Q3 | -26.67 Million USD | 55.51% |
2021 Q2 | -59.94 Million USD | -4.95% |
2021 Q1 | -57.11 Million USD | -2.2% |
2020 Q1 | -15.67 Million USD | 0.0% |
2020 FY | -137.02 Million USD | -91.38% |
2020 Q3 | -34.41 Million USD | -10.81% |
2020 Q4 | -55.88 Million USD | -62.4% |
2020 Q2 | -31.05 Million USD | -98.19% |
2019 FY | -71.59 Million USD | 0.0% |
2001 Q1 | -674.51 Million USD | 0.0% |
2001 Q3 | -653.02 Million USD | -0.94% |
2001 FY | -234.5 Million USD | 0.0% |
2001 Q2 | -646.9 Million USD | 4.09% |
Name | Operating Income | Operating Income Difference |
---|---|---|
ADC Therapeutics SA | -165.98 Million USD | -420.77% |
Alto Neuroscience, Inc. | -37.8 Million USD | -2186.244% |
Annovis Bio, Inc. | -45.03 Million USD | -1819.409% |
Biohaven Pharmaceutical Holding Company Ltd. | -436.05 Million USD | -98.235% |
Nuvation Bio Inc. | -99.82 Million USD | -765.947% |
Nuvation Bio Inc. | -99.82 Million USD | -765.947% |
Arcus Biosciences, Inc. | -340 Million USD | -154.237% |
Zymeworks Inc. | -138.05 Million USD | -526.141% |